Report cover image

Roche Holding AG (ROG:SWF) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends

Publisher Quaintel Research
Published Oct 29, 2024
Length 133 Pages
SKU # QTELR19285204

Description

Roche Holding AG (ROG:SWF) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends


Report Summary

Roche Holding AG (ROG:SWF) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of Roche Holding AG's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Roche Holding AG including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Roche Holding AG's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Roche Holding AG's overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Roche Holding AG's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Roche Holding AG's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by Roche Holding AG enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Roche Holding AG operates as a research-focused healthcare company in the pharmaceuticals and diagnostics businesses. Roche Holding AG operates in two main segments: pharmaceuticals and diagnostics. Roche Holding AG offers a range of pharmaceutical products for therapeutic areas including oncology, neuroscience, infectious diseases, immunology, ophthalmology, and transplantation. The company also provides in vitro diagnostic tests for diseases like cancer, cardiovascular conditions, diabetes, hepatitis, and COVID-19. Roche supplies diagnostic instruments and reagents as well. Founded in 1896, the company is headquartered in Basel, Basel-Stadt, Switzerland.

Roche Holding AG in the News:-
  • 26-Sep-2024 - Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
  • 24-Sep-2024 - Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
  • 23-Sep-2024 - WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
  • 19-Sep-2024 - Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
  • 16-Sep-2024 - FDA approves OCREVUS ZUNOVO as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
Scope
  • Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
  • Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
  • Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
  • Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
  • Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
  • Comprehensive Understanding of the Roche Holding AG's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
  • Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
  • Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
  • Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
  • Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
  • Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Roche Holding AG:
  • Roche Holding AG Value Chain Analysis
  • Roche Holding AG Porter's Five Forces Analysis
  • Roche Holding AG VRIO Analysis
  • Roche Holding AG BCG Analysis
  • Roche Holding AG Segmentation, Targeting and Positioning (STP) Analysis
  • Roche Holding AG Ansoff Matrix Analysis

Table of Contents

133 Pages
COMPANY EXECUTIVE SUMMARY
Tables
Charts
Roche Holding AG - Key Company Facts
Roche Holding AG - Company Description
Roche Holding AG - Top Executives
Roche Holding AG- Top Executives Biographies
Roche Holding AG- Head Office & Locations
Head Office - Country
Key Subsidiaries
Roche Holding AG - Products and Services
Products
Services
Roche Holding AG - Historic Events
Roche Holding AG - Company's Management Discussion
Roche Holding AG - Company's Mission and Vision
Mission
Roche Holding AG - Corporate Strategy
Roche Holding AG - Business Description
Pharmaceuticals Division
Diagnostics Division
Roche Holding AG - ESG Spotlight
Environment
Social
Corporate Governance
Roche Holding AG - SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Roche Holding AG - PESTLE Analysis
Overview
Political Factors
Economic Factors
Social Factors
Technological Factors
Legal Factors
Environmental Factors
Roche Holding AG - Financial Deep Dive
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price)
Profit and Loss Statement
Summary of Profit and Loss Statement
Balance Sheet
Summary of Balance Sheet
Cash Flow Statement
Summary of Cash Flow Statement
Key Financial Ratio Analysis
Roche Holding AG - Ratio Charts
Activity Ratio Charts
Growth Ratios Charts
Leverage Ratio Charts
Liquidity Ratio Charts
Profitability Ratio Charts
Competing Players
Snapshot of Competing Players
AbbVie Inc
Key Company Facts
Company Description
Snapshot of Competing Players
Bristol-Myers Squibb Company
Key Company Facts
Company Description
Snapshot of Competing Players
Eli Lilly and Company
Key Company Facts
Company Description
Snapshot of Competing Players
GSK plc
Key Company Facts
Company Description
Snapshot of Competing Players
Johnson & Johnson
Key Company Facts
Company Description
Snapshot of Competing Players
Merck KGaA
Key Company Facts
Company Description
Snapshot of Competing Players
Novartis AG
Key Company Facts
Company Description
Snapshot of Competing Players
Pfizer Inc.
Key Company Facts
Company Description
Snapshot of Competing Players
Sanofi SA
Key Company Facts
Company Description
Roche Holding AG - In the News
26-Sep-2024- Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
24-Sep-2024- Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
23-Sep-2024- WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche's role in pioneering cervical cancer solutions
19-Sep-2024- Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
16-Sep-2024- FDA approves OCREVUS ZUNOVO as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
07-Sep-2023- Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
29-Aug-2023- European Commission approves Roche's Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
11-Jul-2023- European Commission approves Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
09-May-2023- FDA accepts application for Roche's Vabysmo for the treatment of retinal vein occlusion (RVO)
26-Apr-2023- CHMP recommends EU approval of Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
16-Apr-2023- Roche's Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
23-Feb-2023- Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
01-Feb-2023- European Commission approves label expansion of Roche's Hemlibra to include people with moderate haemophilia A in the EU
06-Jan-2023- FDA grants priority review to Roche's bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
13-Jun-2013- Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries
Roche Holding AG- Key Deals
07-Sep-2022 - Roche snaps up PD-1-focused Good Therapeutics for $250M; 'Sky's the limit' for spinout
02-Dec-2021 - Roche acquires test maker TIB Molbiol
15-Sep-2021 - Roche Acquires TIB Molbiol to Boost Molecular Diagnostics Profile
15-Mar-2021 - Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample
24-Sep-2020 - Roche buys Inflazome for $445 million
16-Sep-2020 - Roche acquires Kapa Biosystems
17-Dec-2019 - The Wait Is Over: After Multiple Delays, Roche Completes Acquisition of Spark Therapeutics
25-Feb-2019 - Spark Therapeutics Enters into Definitive Merger Agreement with Roche
25-Feb-2019 - Roche acquires Spark in $4.8B gene therapy play
07-Apr-2018 - Roche Completes Acquisition of Flatiron Health
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Financial Deep Dive
Financial Ratios -
Activity Ratios
Growth Ratios
Leverage Ratios
Liquidity Ratios
Market Ratios
Profitability Ratios
Research Methodology
Disclaimer
Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us